Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.1
Equity-to-Asset	0.2
Debt-to-Equity	2.05
Debt-to-EBITDA	2.71
Interest Coverage	21.4
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	11.44	Distress Grey Safe
Beneish M-Score	-1.87	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	12
	3-Year EBITDA Growth Rate	-1
	3-Year EPS without NRI Growth Rate	0.8
	3-Year Book Growth Rate	26.6
	Future 3-5Y EPS without NRI Growth Rate	57.13
	Future 3-5Y Total Revenue Growth Rate	22.86

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	69.6
	9-Day RSI	67.87
	14-Day RSI	67.77
	6-1 Month Momentum %	41.7
	12-1 Month Momentum %	106.52

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.35
	Quick Ratio	1.03
	Cash Ratio	0.14
	Days Inventory	267.46
	Days Sales Outstanding	81.64
	Days Payable	122.85

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.52
	Dividend Payout Ratio	0.48
	3-Year Dividend Growth Rate	15.2
	Forward Dividend Yield %	0.56
	5-Year Yield-on-Cost %	1.05
	3-Year Average Share Buyback Ratio	2
	Shareholder Yield %	-0.16

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	80.16
	Operating Margin %	33.51
	Net Margin %	17.08
	FCF Margin %	-10.87
	ROE %	53.79
	ROA %	10.45
	ROIC %	22.81
	ROC (Joel Greenblatt) %	63.55
	ROCE %	21.26
	Years of Profitability over Past 10-Year	9

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	139.98
	Forward PE Ratio	69.44
	PE Ratio without NRI	97.19
	Shiller PE Ratio	178.84
	PEG Ratio	9.08
	PS Ratio	23.87
	PB Ratio	66.8
	Price-to-Tangible-Book	772.3
	Price-to-Operating-Cash-Flow	233.07
	EV-to-EBIT	108.25
	EV-to-Forward-EBIT	59.48
	EV-to-EBITDA	90.76
	EV-to-Forward-EBITDA	54.48
	EV-to-Revenue	24.47
	EV-to-Forward-Revenue	20.43
	EV-to-FCF	-225.73
	Price-to-Projected-FCF	16.65
	Price-to-Median-PS-Value	4.21
	Price-to-Peter-Lynch-Fair-Value	10.37
	Price-to-Graham-Number	57.72
	Earnings Yield (Greenblatt) %	0.92
	FCF Yield %	-0.46
	Forward Rate of Return (Yacktman) %	9.7

GF Value: €418.88

XTER:LLY

Warning Signs

Warning! GuruFocus detected 6 Medium warning signs with LLY. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.